The global Anti-Suicide
Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs,
Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), by Region (North
America, Latin America, Europe, Asia Pacific, Middle East and Africa) was
valued at US$ 3,818.1 million in 2018 and is projected to expand at a CAGR of
4.1% during the forecast period (2019–2027). Introduction of novel approved
drugs, expected to be commercialized post-2020, intended for treatment of
suicidal ideation would be a major breakthrough for the global anti-suicide
drugs market. Until recently, suicidal ideation has been treated with
anti-depressants, anti-anxiety, and anti-psychotic drugs. The trend would
continue until the expected launch of Cyclurad by NeruoRx Pharma during the
latter half of the forecast period (2019–2027). Cyclurad is a combination of
D-cycloserine and Lurasidone and indicated for Acute Suicidal Ideation/Behavior
(ASIB) in Bipolar Depression. Other drug candidates are also in the pipeline,
intended for treatment of suicidal ideation in major depressive disorder (MDD).
Browse 48 Market Data Tables and
44 Figures spread through 150 Pages and in-depth TOC on " Anti-Suicide
Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs,
Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), by Region (North
America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Global
Forecast to 2027"
Suicide is among the major
economic burdens to the global economy. According to the World Health
Organization (WHO), over 800,000 people commit suicide every year. Most of the
suicidal deaths occur in Asia, Africa, and Eastern Europe. Moreover, many
suicidal attempts go unnoticed until and seldom are reported to suicidal
prevention organizations, who can help alleviate the issue. Stop Suicide,
Yellow Ribbon Suicide Prevention Program, and American Foundation for Suicide
Prevention are some of the leading organizations working for preventing
suicides.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/10
Sneha India Foundation is also
one of the major organization in India who provide 24X7 helpline in order to
offers unconditional emotional support to desperate, depressed and suicidal
people. High prevalence of depression that leads to suicidal attempts and
deaths would be another stimulus besides the introduction of novel drugs for
the growth of anti-suicide drugs market. According to the FDA, depression act
as a disabling and stigmatizing illness which may lead to suicide among young
people and adolescents. Thus, launch of specific drugs for suicidal impulses by
pharmaceutical companies will prove to be a profitable market in the foreseen
future. N-Methyl-D-aspartate receptor (NMDAR) agonists and antagonist are the
prospective candidate for treating suicidal ideation. Companies banking on
anti-depressants and anti-psychotic drugs for treating patients at risk for
suicide should reconsider their strategy, considering these are not very
effective at addressing the issue. Nonetheless, these drug class are not
approved for use in treating patients at risk for suicide. The global
anti-suicide drugs market has been driven majorly by off-label recommendations
and prescriptions of anti-depressants, anti-anxiety and anti-psychotic drugs.
Inadequate reach of healthcare facilities and affordable medications is hindering
growth of overall healthcare market in emerging economies such as India, China,
Brazil, and Indonesia. Therefore, companies introducing novel anti-suicidal
drugs would be facing a challenge in market penetration in these nations and
would be able to capture only a part of these markets to capitalize on the
lucrative growth opportunities in these regions. North America and Europe
remain potential markets at initial stages for the anti-suicidal drugs. High
suicidal rates and accessibility to better medical therapies would be the major
contributing factors for the anti-suicide drugs market in these regions.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/anti-suicide-drugs-market-10
Key takeaways of the market:
The global anti-suicide drugs
market is majorly characterized by the use of anti-depressants, anti-anxiety
and anti-psychotic drugs
The global anti-suicide drugs
market is expected to expand at a CAGR of 4.1% during the forecast period
(2019–2027). Rising incidence of suicides across the globe is expected to favor
the market growth for anti-suicide drugs over the forecast period.
Suicidal rates are higher in
Asia, Eastern Europe and Africa regions
The antibiotic analog (NMDA
agonist) segment in the global anti-suicide drugs market is estimated to be
growing faster post its FDA approval and commercialization
Market growth for
anti-depressants and anti-anxiety drugs is projected to be impacted negatively
by the launch of FDA approved anti-suicidal drugs expected towards the
latter-half of the forecast period
Some of the major players present
in the global anti-suicide drugs market are Pfizer, Inc., AstraZeneca plc, Eli
Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H.
Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/10
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
